All In MedTech

Device Trial Radar · NCT06112418

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

A Randomized Comparison of Cleerly Coronary Artery Disease Stage-Based Care Versus Risk Factor-Based Care for Primary Prevention of Cardiovascular Events

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 7,500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

7,500

Planned (sponsor's estimate)

Start

Mar 6, 2024

Primary completion

Mar 5, 2029

Study completion Mar 5, 2029

Sponsor

Lead sponsor
Cleerly, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
CPC Clinical Research
First posted
Nov 1, 2023

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated device
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

TRANSFORM is a prospective, randomized, open blinded endpoint (PROBE), event-driven, pragmatic trial in patients who are at increased risk for atherosclerotic cardiovascular (CV) disease but with no known symptomatic CV disease. The trial tests the hypothesis that a Cleerly Coronary Artery Disease (CAD) Staging System-based care strategy reduces CV events compared with risk factor-based care.

Conditions

  • Diabetes Mellitus, Type 2
  • PreDiabetes
  • Metabolic Syndrome

Interventions

  • The Cleerly CAD Staging SystemDevice

    The Cleerly CAD Staging System is software that utilizes a proprietary algorithm to identify CAD, stage the severity of CAD when present, and generate a prognostic risk score to inform treatment decisions that support CV disease prevention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary objective is to compare Cleerly stage-based care with risk factor-based care on the risk of CV events.Time frame: Through study completion- an average of 3.5 years

Locations

125 sites in 1 country. Site status is shown where the registry gives one.

  • Chandler Clinical Trials

    Chandler, Arizona · Recruiting

  • Scottsdale Clinical Trials

    Scottsdale, Arizona · Recruiting

  • Sun City Research

    Sun City, Arizona · Recruiting

122 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.